Maribavir
- Generic Name
- Maribavir
- Brand Names
- Livtencity
- Drug Type
- Small Molecule
- Chemical Formula
- C15H19Cl2N3O4
- CAS Number
- 176161-24-3
- Unique Ingredient Identifier
- PTB4X93HE1
- Background
Maribavir is an inhibitor of the cytomegalovirus (CMV; HHV5) pUL97 kinase which is used to treat CMV infections in patients post-transplantation. Most standard CMV therapies, such as ganciclovir or foscarnet, target CMV DNA polymerase - while generally effective, these medications tend to promote the development of CMV resistance to DNA polymerase-based ther...
- Indication
Maribavir is indicated for the treatment of post-transplant cytomegalovirus (CMV) infection (following hematopoietic stem cell transplant or solid organ transplant) which is refractory to standard treatment with ganciclovir, valganciclovir, cidofovir, or foscarnet.
...
- Associated Conditions
- Post-transplant Cytomegalovirus (CMV) Infection
- Associated Therapies
- -
Study of SHP620 (Maribavir) in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Shire
- Target Recruit Count
- 18
- Registration Number
- NCT02775240
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Shire
- Target Recruit Count
- 120
- Registration Number
- NCT01611974
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Emory University, Atlanta, Georgia, United States
Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients
- First Posted Date
- 2007-07-09
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Shire
- Target Recruit Count
- 307
- Registration Number
- NCT00497796
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
- First Posted Date
- 2006-12-14
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Shire
- Target Recruit Count
- 681
- Registration Number
- NCT00411645
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸Jeanes Hospital - Temple, Philadelphia, Pennsylvania, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
Maribavir for Prevention of CMV After Stem Cell Transplants
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Shire
- Target Recruit Count
- 111
- Registration Number
- NCT00223925
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Loyola University, Maywood, Illinois, United States
🇺🇸Duke Medical Center, Durham, North Carolina, United States
The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 56
- Registration Number
- NCT00002373
- Locations
- 🇺🇸
Univ of California/ San Francisco / Dept of Medicine, San Francisco, California, United States
🇺🇸Dr Jacob Lalezari, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.